MiMedx Q3 net sales $67.7M (+7.3% YoY); net loss widens to $8.4M; launches two surgical products

MIMEDX GROUP, INC.

2022-Q3 EPS reported -$0.31 revenue$193,466,000

Net sales $67.7M, up 7.3% YoY; net loss $8.4M vs $2.3M loss prior year; adjusted EBITDA loss $0.7M vs gain $7.0M.
Launched AXIOFILL and AMNIOEFFECT for surgical recovery; obtained Japan reimbursement for EPIFIX.
Appointed Todd Newton interim CEO; new segment reporting for Wound & Surgical and Regenerative Medicine.
Advanced KOA registrational study with FDA, including Type B RMAT meeting and CMC filings.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MIMEDX GROUP, INC. reported third quarter ended September 30, 2022 results: revenue $67.7 million, net income $8.4 million, EPS $ (0.09 ).

Period: third quarter ended September 30, 2022
Revenue: $67.7 million
Net income: $8.4 million
EPS: $ (0.09 )
Result: reported results

Exact text from the filing

Key Third Quarter 2022 Financial Metrics • Net sales of $67.7 million for third quarter 2022, compared to $63.1 million for the prior year period. • Net loss of $8.4 million for third quarter 2022, compared to a net loss of $2.3 million for the prior year period. • Adjusted EBITDA 1 loss of $0.7 million for third quarter 2022, compared to a gain of $7.0 million for the prior year period. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) (in thousands) 2022 2021 2022 2021 Net sales $ 67,689 $ 63,074 $ 193,466 $ 191,206 Net loss (8,426 ) (2,339 ) (29,783 ) (12,500 ) EBITDA 1 (6,097 ) 41 (22,971 ) (4,302 ) Adjusted EBITDA 1 (724 ) 7,022 (3,402 ) 15,117 Net loss per common share - basic $ (0.09 ) $ (0.04 ) $ (0.31 ) $ (0.15 ) Net loss per common share - diluted $ (0.09 ) $ (0.04 ) $ (0.31 ) $ (0.15 )

View on SEC.gov

Browse all earnings releases →

MIMEDX GROUP, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-275856

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.